转移性人表皮生长因子受体2阳性乳腺癌的治疗变迁
The changing treatment of metastatic her2-positive breast cancer.
作者信息
Mitsogianni Maria, Trontzas Ioannis P, Gomatou Georgia, Ioannou Stephanie, Syrigos Nikolaos K, Kotteas Elias A
机构信息
Oncology Unit, 'Sotiria' General Hospital, Athens School of Medicine, Athens 11527, Greece.
出版信息
Oncol Lett. 2021 Apr;21(4):287. doi: 10.3892/ol.2021.12548. Epub 2021 Feb 12.
Abstract
Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer has been historically associated with an aggressive disease course with common distant metastasis and poor prognosis. HER2-targeting therapies have significantly changed treatment and drastically improved outcomes for this group of patients. However, primary or acquired resistance to anti-HER2 regimens leads almost universally to disease progression, often with difficult to treat central nervous system (CNS) metastases. The current review summarized the existing therapeutic options for HER2-positive metastatic disease in the first, second and further line setting. Furthermore, novel agents currently under development were presented, which have demonstrated encouraging results in heavily pretreated patients or specific subgroups, such as HR-positive/HER2-positive tumors and CNS disease.
摘要
人表皮生长因子受体2（HER2）过表达的乳腺癌在历史上一直与侵袭性病程相关，常发生远处转移且预后较差。针对HER2的疗法显著改变了治疗方式，并极大地改善了这组患者的治疗效果。然而，对抗HER2方案的原发性或获得性耐药几乎普遍导致疾病进展，且常伴有难以治疗的中枢神经系统（CNS）转移。本综述总结了HER2阳性转移性疾病一线、二线及后续治疗中的现有治疗选择。此外，还介绍了目前正在研发的新型药物，这些药物在经过大量预处理的患者或特定亚组中，如激素受体（HR）阳性/HER2阳性肿瘤和CNS疾病，已显示出令人鼓舞的结果。
相似文献
1
The changing treatment of metastatic her2-positive breast cancer.转移性人表皮生长因子受体2阳性乳腺癌的治疗变迁
Oncol Lett. 2021 Apr;21(4):287. doi: 10.3892/ol.2021.12548. Epub 2021 Feb 12.
2
Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.腔面亚型预测手术治疗转移性乳腺癌患者中枢神经系统转移后生存改善。
Arch Pathol Lab Med. 2014 Feb;138(2):175-81. doi: 10.5858/arpa.2012-0541-OA.
3
New protein kinase inhibitors in breast cancer: afatinib and neratinib.乳腺癌中的新型蛋白激酶抑制剂：阿法替尼和来那替尼。
Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30.
4
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.人表皮生长因子受体2阳性转移性乳腺癌患者的当前治疗方法
Front Oncol. 2018 Apr 3;8:89. doi: 10.3389/fonc.2018.00089. eCollection 2018.
5
Defining prognosis for women with breast cancer and CNS metastases by HER2 status.根据HER2状态定义乳腺癌合并中枢神经系统转移女性的预后。
Ann Oncol. 2008 Jul;19(7):1242-1248. doi: 10.1093/annonc/mdn036. Epub 2008 Mar 11.
6
Trastuzumab and survival of patients with metastatic breast cancer.曲妥珠单抗与转移性乳腺癌患者的生存率
Arch Gynecol Obstet. 2017 Aug;296(2):303-312. doi: 10.1007/s00404-017-4421-x. Epub 2017 Jun 14.
7
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.接受一线曲妥珠单抗治疗的HER2过表达晚期乳腺癌患者的孤立性中枢神经系统转移
Ann Oncol. 2005 Nov;16(11):1772-7. doi: 10.1093/annonc/mdi371. Epub 2005 Sep 8.
8
Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.人表皮生长因子受体2阳性转移性乳腺癌的治疗策略：文献综述
Cureus. 2020 Aug 2;12(8):e9522. doi: 10.7759/cureus.9522.
9
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.人表皮生长因子受体2阳性乳腺癌的靶向治疗——一项系统评价
Breast Care (Basel). 2015 Jul;10(3):173-8. doi: 10.1159/000431029. Epub 2015 Jun 18.
10
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.依维莫司联合依西美坦治疗激素受体阳性晚期乳腺癌：BOLERO-2 研究的 PAM50 内在亚型分析。
Oncologist. 2019 Jul;24(7):893-900. doi: 10.1634/theoncologist.2018-0407. Epub 2019 Jan 24.
引用本文的文献
1
Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.脑肿瘤的近红外光免疫疗法——一个未被探索的前沿领域。
Pharmaceuticals (Basel). 2025 May 19;18(5):751. doi: 10.3390/ph18050751.
2
HERmione: Understanding the Needs of Patients Living with Metastatic HER2-Positive Breast Cancer Through a Cross-Sectional Survey in Parallel with Patients and Oncologists.赫敏：通过与患者和肿瘤学家同步进行的横断面调查了解HER2阳性转移性乳腺癌患者的需求。
Cancers (Basel). 2025 Apr 17;17(8):1349. doi: 10.3390/cancers17081349.
3
Characterization of Breast Cancer Aggressiveness by Cell Mechanics.基于细胞力学特性对乳腺癌侵袭性的研究
Int J Mol Sci. 2023 Jul 30;24(15):12208. doi: 10.3390/ijms241512208.
4
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.用于抗体增强肿瘤清除的首个 HER2、Brachyury 和 CD40L 编码疫苗的临床前开发。
Sci Rep. 2023 Mar 30;13(1):5162. doi: 10.1038/s41598-023-32060-2.
5
Surface plasmon resonance biosensor for exosome detection based on reformative tyramine signal amplification activated by molecular aptamer beacon.基于分子适体信标激活的改良酪胺信号放大的外泌体检测表面等离子体共振生物传感器。
J Nanobiotechnology. 2021 Dec 24;19(1):450. doi: 10.1186/s12951-021-01210-x.
6
Valproic Acid and Breast Cancer: State of the Art in 2021.丙戊酸与乳腺癌：2021年的最新进展
Cancers (Basel). 2021 Jul 7;13(14):3409. doi: 10.3390/cancers13143409.
本文引用的文献
1
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.奈拉替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌：NALA Ⅲ期临床试验。
J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17.
2
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.HER2阳性晚期乳腺癌的新型疗法：临床实践会因此改变吗？π
Cancers (Basel). 2020 Jun 14;12(6):1573. doi: 10.3390/cancers12061573.
3
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.在 HER2CLIMB 试验中，曲妥珠单抗联合卡培他滨治疗既往治疗的 HER2 阳性乳腺癌伴脑转移的颅内疗效和生存。
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
4
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.基于 CDK4/6 抑制剂的治疗在转移性乳腺癌临床相关亚组中的总生存期：系统评价和荟萃分析。
J Natl Cancer Inst. 2020 Nov 1;112(11):1089-1097. doi: 10.1093/jnci/djaa071.
5
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.阿贝西利联合曲妥珠单抗和（或）氟维司群对比曲妥珠单抗联合标准治疗化疗用于激素受体阳性、HER2 阳性晚期乳腺癌患者（monarcHER）：一项随机、开放标签、二期临床试验。
Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27.
6
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于治疗人表皮生长因子受体 2（HER2）阳性转移性乳腺癌（CLEOPATRA）：一项双盲、随机、安慰剂对照、3 期研究的终期结果。
Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
7
Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer.激素治疗联合靶向治疗用于内分泌反应性和HER2阳性转移性乳腺癌
Ther Adv Med Oncol. 2019 Dec 16;11:1758835919894105. doi: 10.1177/1758835919894105. eCollection 2019.
8
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.曲妥珠单抗、曲妥珠单抗和卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.
9
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
10
Breast cancer.乳腺癌。
Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2.
Zotero 插件